Compounding pharmacy represents a regulated segment of the Brazilian pharmaceutical industry that continues to be confused with illicit smuggling activities. According to experts from the Institute of Science, Technology and Quality (ICTQ), this confusion damages the legitimate sector and compromises public understanding of the fundamental differences between the two scenarios.
Compounding pharmacies operate under strict regulation by the National Health Surveillance Agency (ANVISA), following specific standards that establish quality requirements, good manufacturing practices, and sanitary control. These institutions maintain official registration, operating licenses, and are subject to regular inspections.
In contrast, pharmaceutical smuggling is characterized by clandestine importation and distribution of products without documentation, regulatory compliance, or any sanitary oversight. This illegal activity poses significant public health risks, as there are no guarantees regarding the origin, composition, or safety of smuggled products.
The ICTQ points out that the lack of clarity in this distinction generates significant consequences for legitimate compounding pharmacies, affecting their reputation and commercial viability. Simultaneously, this conceptual confusion hampers effective smuggling enforcement, as it compromises understanding among authorities and the public about the characteristics that define each activity.
Regulatory bodies emphasize the importance of reinforcing this differentiation with society, healthcare professionals, and lawmakers. Strengthening understanding about the regulated role of compounding pharmacies is essential to protect both consumers and the legal industry, while intensifying efforts against clandestine activities that represent a genuine threat to public health.
